The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Ceftaroline Restores Daptomycin Activity against Daptomycin-Nonsusceptible Vancomycin-Resistant Enterococcus faecium
Open accessAbstract
Daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium (VRE) strains are a formidable emerging threat to patients with comorbidities, leaving few therapeutic options in cases of severe invasive infections. Using a previously characterized isogenic pair of VRE strains from the same patient differing in their daptomycin susceptibilities (Etest MICs of 0.38 mg/liter and 10 mg/liter), we examined the effect of ceftaroline, ceftriaxone, and ampicillin on membrane fluidity and susceptibility of VRE to surface binding and killing by daptomycin and human cathelicidin antimicrobial peptide LL37. Synergy was noted in vitro between daptomycin, ampicillin, and ceftaroline for the daptomycin-susceptible VRE strain, but only ceftaroline showed synergy against the daptomycin-nonsusceptible VRE strain (∼2 log 10 CFU reduction at 24 h). Ceftaroline cotreatment increased daptomycin surface binding with an associated increase in membrane fluidity and an increase in the net negative surface charge of the bacteria as evidenced by increased poly- l -lysine binding. Consistent with the observed biophysical changes, ceftaroline resulted in increased binding and killing of daptomycin-nonsusceptible VRE by human cathelicidin LL37. Using a pair of daptomycin-susceptible/nonsusceptible VRE strains, we noted that VRE is ceftaroline resistant, yet ceftaroline confers significant effects on growth rate as well as biophysical changes on the cell surface of VRE that can potentiate the activity of daptomycin and innate cationic host defense peptides, such as cathelicidin. Although limited to just 2 strains, these finding suggest that additional in vivo and in vitro studies need to be done to explore the possibility of using ceftaroline as adjunctive anti-VRE therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of in vitro evaluations [214][215][216] suggested that ampicillin and ceftaroline in combination with daptomycin demonstrate the greatest synergistic activity compared with other β-lactam-daptomycin combinations.”
From Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association (2015) · cites this paper as [215]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of multidrug-resistant enterococcal infections
Arias, C. A., Contreras, G. A., & Murray, B. E. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03214.x · Cited by 388
Genetic Basis for In Vivo Daptomycin Resistance in Enterococci
Arias, C. A., Panesso, D., McGrath, D. M., Qin, X., Mojica, M. F., Miller, C., Diaz, L., Tran, T. T., Rincon, S., Barbu, E. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011138 · Cited by 377
Dvorchik, B. H., Brazier, D., DeBruin, M. F., & Arbeit, R. D. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1318-1323.2003 · Cited by 358
Dhand, A., Bayer, A. S., Pogliano, J., Yang, S.-J., Bolaris, M., Nizet, V., Wang, G., & Sakoulas, G. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir340 · Cited by 252 · cited 2×
“MICs to cathelicidin LL37 in RPMI-5% LB for strains 8019 and 5938 were 2 M and 4 M, respectively, consistent with tracking of the susceptibility of daptomycin to cationic antimicrobial peptides (14).”
Self-citationPharmacokinetics of ceftriaxone in humans
Patel, I. H., Chen, S., Parsonnet, M., Hackman, M. R., Brooks, M. A., Konikoff, J., & Kaplan, S. A. (1981) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.20.5.634 · Cited by 244
Linezolid pharmacokinetics and pharmacodynamics in clinical treatment
Dryden, M. S. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr072 · Cited by 198
Sakoulas, G., Bayer, A. S., Pogliano, J., Tsuji, B. T., Yang, S.-J., Mishra, N. N., Nizet, V., Yeaman, M. R., & Moise, P. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05551-11 · Cited by 176
Self-citationMishra, N. N., Bayer, A. S., Tran, T. T., Shamoo, Y., Mileykovskaya, E., Dowhan, W., Guan, Z., & Arias, C. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043958 · Cited by 168
Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus
Sakoulas, G., Okumura, C. Y. M., Thienphrapa, W., Olson, J., Nonejuie, P., Dam, Q., Dhand, A., Pogliano, J., Yeaman, M. R., Hensler, M. E., et al. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1100-7 · Cited by 153
Self-citationDaptomycin Nonsusceptible Enterococci: An Emerging Challenge for Clinicians
Kelesidis, T., Humphries, R. M., Uslan, D. Z., & Pegues, D. A. (2010) · Clinical Infectious Diseases · doi:10.1093/cid/ciq113 · Cited by 145
Self-citation
Research works printed but not linked: 1
- CLSI. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Mechanisms of antibiotic resistance in enterococci
Miller, W. R., Munita, J. M., & Arias, C. A. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.956092 · Cited by 772
“Indeed, combinations of DAP with ampicillin, ceftriaxone and ceftaroline have been noted to be synergistic in vitro and to improve clinical outcomes of patients failing DAP therapy [71–73].”
BackgroundCrank, C., & O'Driscoll, T. (2015) · Infection and Drug Resistance · doi:10.2147/idr.s54125 · Cited by 505
The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent
Ridyard, K. E., & Overhage, J. (2021) · Antibiotics · doi:10.3390/antibiotics10060650 · Cited by 270
“One study found that the combination of DAP and CPT increased the amount of LL-37 binding to the surface of VRE, and therefore sensitizes the bacteria to LL-37 [209].”
BackgroundMechanisms of drug resistance: daptomycin resistance
Tran, T. T., Munita, J. M., & Arias, C. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12948 · Cited by 234
Metadata
- Authors
- Sakoulas, G., Rose, W., Nonejuie, P., Olson, J., Pogliano, J., Humphries, R., & Nizet, V.
- Affiliations
- University of California San Diego (US)
- University of Wisconsin–Madison (US)
- University of California, Los Angeles (US)
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2014-03
- Volume
- 58
- Issue
- 3
- Pages
- 1494-1500
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3957885
- OpenAlex
- W2140427502
- Semantic Scholar
- 7cd7eeff4f3f8161c4beafcf1621194b9b5cae51
- Cited by
- 94
- References
- 23
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 4 · 2023: 6 · 2022: 9 · 2021: 2 · 2020: 4 · 2019: 4 · 2018: 12 · 2017: 14 · 2016: 8 · 2015: 16 · 2014: 7
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Great Lakes Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research
- Medicines Company
- Forest Laboratories
- National Institute of General Medical Sciences (R01GM073898)
- National Institute of Allergy and Infectious Diseases (U54AI057153, R01AI052453, AI057153, R37AI052453)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54 HD071600-01 09/26/2011-06/30/2016, U54HD071600)
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Immunology and Microbiology › Microbiology › Antimicrobial Peptides and Activities
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Keywords
- ceftaroline, daptomycin, vancomycin-resistant Enterococcus faecium, daptomycin resistance, antibiotic synergy, membrane fluidity, cell surface charge, antimicrobial peptides, adjunctive therapy, ceftriaxone, ampicillin, isogenic strains
- MeSH terms
- Ceftaroline, Anti-Bacterial Agents, Cell Wall, Cephalosporins, Drug Synergism, Membrane Fluidity, Microbial Sensitivity Tests, Enterococcus faecium, Daptomycin, Vancomycin Resistance, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ceftaroline Restores Daptomycin Activity against Daptomycin-Nonsusceptible Vancomycin-Resistant Enterococcus faecium. https://app.cochat.ai/papers/10.1128/aac.02274-13
- The paper
- Sakoulas, G., Rose, W., Nonejuie, P., Olson, J., Pogliano, J., Humphries, R., & Nizet, V. (2014). Ceftaroline Restores Daptomycin Activity against Daptomycin-Nonsusceptible Vancomycin-Resistant Enterococcus faecium. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.02274-13
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.